Lal, Shalini http://orcid.org/0000-0002-7501-5018
Gleeson, John F.
D’Alfonso, Simon
Lee, Hajin
Etienne, Geraldine
Joober, Ridha
Lepage, Martin http://orcid.org/0000-0003-4345-6502
Alvarez-Jimenez, Mario
Funding for this research was provided by:
Canada Research Chairs
Brain and Behavior Research Foundation
Article History
Received: 16 January 2023
Accepted: 22 March 2023
First Online: 7 April 2023
Competing interests
: S.L. reports a research grant from Hoffman-La Roche, pertaining to a phase 3 study on the implementation and evaluation of HoryzonsCa; M.A.-J., J.F.G., and R.J. are coinvestigators on this grant. M.A.-J. was supported by an Investigator Grant (APP1177235) from the National Health and Medical Research Council and a Dame Kate Campbell Fellowship from The University of Melbourne. R.J. served as speaker and member of advisory board committees for Pfizer, Janssen, Bristol Myers Squibb, Sunovian, Myelin and Associates, Otsuka, Lundbeck, Shire, and Perdue. He also received grants from Janssen, Bristol Myers Squibb, Otsuka, Lundbeck, Astra Zeneca, and HLS Therapeutics Inc. All of these are unrelated to this study. M.L. reports grants from Otsuka Lundbeck Alliance, Hoffman-La Roche (pertaining to a phase 3 study on the implementation and evaluation of HoryzonsCa), diaMentis, personal fees from Otsuka Canada, personal fees from Lundbeck Canada, grants and personal fees from Janssen, and personal fees from MedAvante-Prophase outside the submitted work. All other authors declare no financial or non-financial competing interests.